Bayer Pulls Remaining Stocks Of Trasylol
May 15th 2008Drug InformationCardiovascular
The US Food and Drug Administration (FDA) announced yesterday, Wednesday 14th May, that Bayer Pharmaceuticals Corporation is withdrawing remaining stocks of its antifibrinolytic drug Trasylol (aprotinin) following the confirmation of the preliminary findings of a study that showed the drug increased risk of death compared to two other drugs used to control bleeding during heart surgery.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
